Circular presentation of the <i>mcr-1</i> containing <i>IncX4</i> plasmid in the colistin susceptible <i>E</i>.<i>coli</i>.

<p>In green the <i>mcr-1</i> sequence. In red the IS10R insertion sequence, interrupting the <i>mcr-1</i> gene at position 572. Arrows indicate open reading frames (ORFs), dark blue ORFs with annotation, light blue ORFs without annotation (hypothetical protein). Numbers indicate nucleotide positions.</p

Antibiotic phenotype with the corresponding molecular resistance of cultured <i>mcr-1</i> containing <i>E</i>.<i>coli</i>.

<p>Antibiotic phenotype with the corresponding molecular resistance of cultured <i>mcr-1</i> containing <i>E</i>.<i>coli</i>.</p

PPD stimulated IFN-γ (A), IL-5 (B), IL-13 (C), TNF-α (D) and IL-10 (E) production in normal birth weight BCG (NBW BCG) and BCG+OPV vaccinated (NBW BCG+OPV) infants.

<p>One dot represents one individual. Horizontal lines represent medians.</p

Comparison of the frequency of cytokine responders in children vaccinated with BCG and with BCG+OPV.

<p>Adjusted for age, sex, MUAC and month of enrolment, subsequent vaccinations.</p

Primers and probe used to screen for the presence of <i>mcr</i>-genes.

<p>Primers and probe used to screen for the presence of <i>mcr</i>-genes.</p

Description of the scar and PPD study population.

<p>Description of the scar and PPD study population.</p

The effect of receiving OPV with BCG at birth on the likelihood of being scar positive at age 2 and 6 months.

<p>Adjusted for sex, MUAC and season of enrolment, and subsequent vaccinations.</p><p>**P = 0.015.</p

Description of the cytokine study population.

<p>Description of the cytokine study population.</p

The effect of receiving OPV with BCG at birth on the likelihood of having an <i>in vivo</i> response to PPD at age 2 months and 6 months.

<p>Adjusted for sex, MUAC and season of enrolment, subsequent vaccinations and assistant.</p><p>**P = 0.056.</p

An overview of the two trials, the periods with missing OPV, and the periods with ongoing subgroup studies in Guinea-Bissau 2004.

<p>An overview of the two trials, the periods with missing OPV, and the periods with ongoing subgroup studies in Guinea-Bissau 2004.</p